Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
Anensen
N
N
Skavland
J
J
Stapnes
C
C
Ryningen
A
A
Børresen-Dale
A-L
AL
Gjertsen
B T
BT
Bruserud
Ø
Ø
D000628:Aminophylline / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D016864:Li-Fraumeni Syndrome / Q000150:complications* / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*; D000072160:Tumor Protein p73; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D025521:Tumor Suppressor Proteins; D014635:Valproic Acid / Q000627:therapeutic use*
D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D000072160:Tumor Protein p73; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D000628:Aminophylline; D014212:Tretinoin; D014635:Valproic Acid